The major pharmacy chain CVS has reached a deal with the federal government to give out a Covid-19 antibody treatment in patients’ homes and long-term care facilities, the company announced on Wednesday, providing a new way for certain high-risk patients to get a drug aimed at keeping them out of the hospital.
The treatment, called bamlanivimab and developed by Eli Lilly, has been administered mainly at hospitals since it received emergency authorization from the Food and Drug Administration less than a month ago.
The three-month pilot with CVS involves just 1,000 doses of the treatment, enough to treat 1,000 Covid-19 patients.
It’s not clear how much impact that will have as the virus is spreading rapidly and demand for treatments is surging.
“We still don’t have a way to deliver it equitably, and I’m not sure that the CVS partnership is necessarily going to improve equity in distribution.”
Eli Lilly, we’re, ”, Robert Goldstein, “, I’m
CVS, Food and Drug, Massachusetts General Hospital
United States, Massachusetts